WO2024243049A3 - Antibodies and uses thereof - Google Patents

Antibodies and uses thereof Download PDF

Info

Publication number
WO2024243049A3
WO2024243049A3 PCT/US2024/029992 US2024029992W WO2024243049A3 WO 2024243049 A3 WO2024243049 A3 WO 2024243049A3 US 2024029992 W US2024029992 W US 2024029992W WO 2024243049 A3 WO2024243049 A3 WO 2024243049A3
Authority
WO
WIPO (PCT)
Prior art keywords
antigen
specifically binds
binding
binding domain
antibodies
Prior art date
Application number
PCT/US2024/029992
Other languages
French (fr)
Other versions
WO2024243049A2 (en
Inventor
Jinze Li
Jianhui Zhou
Vivekananda KEDAGE
Jie Hu
Zhenfei NING
Jintao FENG
Martin Treder
Zhentao SHENG
Su Huang
Original Assignee
Ltz Therapeutics Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ltz Therapeutics Inc. filed Critical Ltz Therapeutics Inc.
Publication of WO2024243049A2 publication Critical patent/WO2024243049A2/en
Publication of WO2024243049A3 publication Critical patent/WO2024243049A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The disclosure relates to anti-NKp46 antibodies, antigen-binding fragments, and the uses thereof. The disclosure also relates to an antibody or antigen-binding fragment thereof, comprising a first antigen-binding domain that specifically binds to a tumor associated antigen (TAA) and a second antigen-binding domain that specifically binds to an NK cell surface antigen, and an Fc region with optimized Fc-effector function.
PCT/US2024/029992 2023-05-19 2024-05-17 Antibodies and uses thereof WO2024243049A2 (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
CN2023095161 2023-05-19
CNPCT/CN2023/095163 2023-05-19
CN2023095163 2023-05-19
CNPCT/CN2023/095161 2023-05-19
CNPCT/CN2023/137348 2023-12-08
CN2023137348 2023-12-08
CNPCT/CN2023/137346 2023-12-08
CN2023137346 2023-12-08

Publications (2)

Publication Number Publication Date
WO2024243049A2 WO2024243049A2 (en) 2024-11-28
WO2024243049A3 true WO2024243049A3 (en) 2025-01-16

Family

ID=93590415

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/029992 WO2024243049A2 (en) 2023-05-19 2024-05-17 Antibodies and uses thereof

Country Status (1)

Country Link
WO (1) WO2024243049A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012075340A2 (en) * 2010-12-01 2012-06-07 Alderbio Holdings Llc Anti-ngf compositions and use thereof
US20200131268A1 (en) * 2014-06-27 2020-04-30 Innate Pharma NKp46 BINDING PROTEINS
WO2022138692A1 (en) * 2020-12-23 2022-06-30 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecules with improved cytosol-penetrating activity

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012075340A2 (en) * 2010-12-01 2012-06-07 Alderbio Holdings Llc Anti-ngf compositions and use thereof
US20200131268A1 (en) * 2014-06-27 2020-04-30 Innate Pharma NKp46 BINDING PROTEINS
WO2022138692A1 (en) * 2020-12-23 2022-06-30 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecules with improved cytosol-penetrating activity

Also Published As

Publication number Publication date
WO2024243049A2 (en) 2024-11-28

Similar Documents

Publication Publication Date Title
CN112703013A (en) CD3 antigen binding fragment and application thereof
AU6760700A (en) Ovarian cancer cell and myeloma cell surface glycoproteins, antibodies thereto, and uses thereof
NZ547157A (en) Interferon Alpha Antibodies and their uses
WO2002016401A3 (en) Monoclonal antibody ds6, tumor-associated antigen ca6, and methods of use thereof
EP2301968A3 (en) Humanized monoclonal antibody HPAM4
JP2020530272A5 (en)
WO2005056600B1 (en) Monoclonal antibodies that bind or neutralize dengue virus
ES2572231T3 (en) Human anti-IL-21 monoclonal antibodies
CY1107858T1 (en) CCR5 OPTIONS PA14
MX2021004058A (en) Antibody constructs binding 4-1bb and tumor-associated antigens and uses thereof.
CA3242520A1 (en) Tetrahedral antibodies
WO2022216811A3 (en) Chimeric antigen receptor comprising an anti-cd19 antibody or antigen-binding fragment thereof and natural killer cells comprising the same
PH12020551808A1 (en) Antibody variant combinations and uses thereof
PE20232050A1 (en) ANTI-CD19 ANTIBODIES AND CAR-T STRUCTURES
EP4161556A4 (en) Method for selecting antibody fragments, recombinant antibodies produced therefrom, and uses thereof
WO2024243049A3 (en) Antibodies and uses thereof
MX2024014324A (en) Anti-ror1 antibody and ror1-targeting engineered cells
WO2008112891A3 (en) Monoclonal antibody that recognizes a seneca valley virus (svv) cellular receptor and uses thereof
CO2021013836A2 (en) Modification of an antibody for selective tumor binding of cd47
WO2021041300A3 (en) Bispecific antibodies and uses thereof
WO2006131953A3 (en) Antibodies directed against the myelin basic protein recognising an epitope of cd64 and their use as immunosuppressants
WO2025015234A3 (en) Multispecific antibodies and uses thereof
WO2022002801A3 (en) HSV gE ANTIBODIES
AUPS021402A0 (en) Novel monoclonal antibody and nematode larval antigens
PH12023550019A1 (en) Antibodies which bind to cancer cells and target radionuclides to said cells